Skip to main content
Premium Trial:

Request an Annual Quote

UK Group to Sequence Osteosarcoma Patients; Develop Personalized Tests to Monitor Treatment Response


A consortium of researchers in the UK plans to sequence the whole genomes of 50 patients with osteosarcoma, and the whole-exomes of 100 additional samples, in an effort to develop personalized blood tests for patients and identify novel genes involved in the disease.

The research is being funded by the Skeletal Cancer Action Trust, and involves researchers and clinicians from the University College London Cancer Institute, the Royal National Orthopaedic Hospital, and the Wellcome Trust Sanger Institute.

The goal of the project is two-fold: the exome sequencing portion of the study will look for genes that underlie the genesis of the disease, while whole-genome sequencing of patients' plasma will be used to look for patient-specific rearrangements that can be used as the basis for a test.

Patients will be sequenced both before and after treatment with chemotherapy to see if the specific mutations could be used as biomarkers to monitor how individual patients are responding to treatment.

Currently, osteosarcoma patients are monitored by using imaging techniques to scan tumors. This method contrasts with blood cancers, which are "monitored using simple tests that pick up recurring mutations in tumor cells in the blood and show how a patient is responding to treatment," Peter Campbell, a group leader at the Wellcome Trust Sanger Institute, said in a statement. The new project will try and develop similar tests for osteosarcomas.

"We hope that this research project will improve the way patients with cancer are monitored and will guide the best drug treatment for the cancer in each patient," Adrienne Flanagan from the UCL Cancer Institute and Medical Director of the Royal National Orthopaedic Hospital, said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.